Learning Activity 3: Self Assessment, Evaluation, and Credit Application Form

Please note that to receive credit you must achieve a score of at least 80%.

Physicians/Physician Assistants: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.

Pharmacists: The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.

Question Title

1. According to SHEA/IDSA guidelines, what is the first-line oral treatment for mild-to-moderate C. difficile infection?

Metronidazole

Vancomycin

Fidaxomicin

Metronidazole plus vancomycin

Question Title

2. According to SHEA/IDSA guidelines, what is the first-line oral treatment for severe C. difficile infection?

Metronidazole

Vancomycin

Fidaxomicin

Metronidazole plus vancomycin

Question Title

3. According to the SHEA/IDSA guidelines, one of the criteria for severe CDI includes:

Serum albumin at a lower concentration than prior to infection.

Temperature >100.4ᵒF.

White blood cell count >15,000.

Three or more stools per day.

Question Title

4. Clinical studies with fidaxomicin versus vancomycin revealed that:

Fidaxomicin was superior to vancomycin in treating initial episodes of CDI.

Vancomycin was superior to fidaxomicin against infections caused by the BI/NAP1/027 strain.

Fidaxomicin was superior to vancomycin in preventing recurrence.

Vancomycin was superior to fidaxomicin in treating initial and recurrent episodes of CDI.

Question Title

5. Pulse dosing is an option for the treatment of C. difficile infection when using which agent?

Metronidazole

Vancomycin

Nitazoxanide

Rifampin